Journal SAM (April 2013): Dynamic Bone Imaging with 99mTc-Labeled Diphosphonates and 18F-NaF: Mechanisms and Applications

MOC Part II SAM Modules

Journal SAM: Dynamic Bone Imaging with 99m Tc-Labeled Diphosphonates and 18F-NaF: Mechanisms and Applications
Release Date: 9/27/2013
Expiration Date: 9/27/2016

Credit Info.

ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment.   2.0 SAMs have been awarded for this activity.

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity. To receive CE credit, learners must achieve a score of 80% on the post-course assessment and complete the evaluation.


Objectives

Upon successful completion of this activity, participants should be able to:

1. Appreciate the physiologic mechanisms underlying uptake of bone-seeking radiopharmaceuticals used to assess bone perfusion and turnover and note the differences between 18F-NaF and 99mTc-labeled diphosphonates.
2. Discuss the use of bone scintigraphy for evaluation of bone viability and metabolic bone disorders and appreciate the potential role of quantitative dynamic 18F-NaF PET for evaluation of response to therapy.
3. Discuss indications for 99mTc-labeled diphosphonate bone scans and 18F-NaF PET/CT for oncologic staging and appreciate quantitative methods on static and dynamic bone imaging as imaging biomarkers of treatment response using novel systemic therapies for metastatic castrate-resistant prostate cancer as a model.
Target Audience

Journal SAMs are designed for all nuclear medicine specialists and other physicians, pharmacists and technologists who practice diagnostic and/or therapeutic nuclear medicine.

Faculty Disclosure(s)

Ka Kit Wong
Nuclear Medicine/Radiology Department, University of Michigan Hospital, Ann Arbor, Michigan

Morand Piert
Nuclear Medicine Service, Department of Veterans Affairs Health System, Ann Arbor, Michigan

In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.